Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s share price fell 3.3% during trading on Thursday . The stock traded as low as C$3.18 and last traded at C$3.19. 14,359 shares traded hands during trading, an increase of 94% from the average session volume of 7,410 shares. The stock had previously closed at C$3.30.
Eupraxia Pharmaceuticals Trading Down 3.3 %
The firm has a fifty day moving average of C$3.00 and a 200 day moving average of C$2.76.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- Best Stocks Under $5.00
- Micron Stock Under $100: Seize the AI-Driven Upside
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
